Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension

BACKGROUND: Inflammation and dysregulated immunity are important in the development of pulmonary arterial hypertension (PAH). Compelling preclinical data supports the therapeutic blockade of interleukin-6 (IL-6) signalling. METHODS: We conducted a phase 2 open-label study of intravenous tocilizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Toshner, Mark, Church, Colin, Harbaum, Lars, Rhodes, Christopher, Villar Moreschi, Sofia S., Liley, James, Jones, Rowena, Arora, Amit, Batai, Ken, Desai, Ankit A., Coghlan, John G., Gibbs, J. Simon R., Gor, Dee, Gräf, Stefan, Harlow, Louise, Hernandez-Sanchez, Jules, Howard, Luke S., Humbert, Marc, Karnes, Jason, Kiely, David G., Kittles, Rick, Knightbridge, Emily, Lam, Brian, Lutz, Katie A., Nichols, William C., Pauciulo, Michael W., Pepke-Zaba, Joanna, Suntharalingam, Jay, Soubrier, Florent, Trembath, Richard C., Schwantes-An, Tae-Hwi L., Wort, S. John, Wilkins, Martin R., Gaine, Sean, Morrell, Nicholas W., Corris, Paul A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2022
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907935/
https://www.ncbi.nlm.nih.gov/pubmed/34588193
http://dx.doi.org/10.1183/13993003.02463-2020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8907935/
https://www.ncbi.nlm.nih.gov/pubmed/34588193
http://dx.doi.org/10.1183/13993003.02463-2020

Ejemplares similares